Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease‐negative first complete remission

More than two courses of consolidation therapy pre-transplantation benefits patients with acute myeloid leukemia in the first complete remission who underwent human leukocyte antigen-matched sibling allografts: a multicenter study

“…Several researchers have demonstrated that for patients with AML in CR1 who underwent myeloablative conditioning [4,5] or non-myeloablative conditioning [6,7] allo-HSCT using allografts either from a matched related donor, a matched unrelated donor, or an umbilical cord blood donor, the outcomes were comparable between patients receiving pre-transplant consolidation chemotherapy with cytarabine and those proceeding directly to transplantation after achieving CR. In contrast to the above studies, we found a beneficial effect of more consolidation chemotherapy pre-transplant on outcomes in the MSDT setting, in accordance with previously published data [8,9,32] . Several reasons might contribute to the different results between others [4–7] and our study.…”

“…In contrast to the above studies, we found a beneficial effect of more consolidation chemotherapy pre-transplant on outcomes in the MSDT setting, in accordance with previously published data. [8,9,32] Several reasons might contribute to the different results between others [4][5][6][7] and our study. First, Tallman et al [4] and Cahn et al [5] studies included patients across more than 100 centers with different conditioning regimens, whereas our study used the same conditioning regimen, making it easier to compare among homogenous samples.…”

“…More recently, a meta-analysis showed no significant benefit of post-remission consolidation chemotherapy in patients with AML who received allo-HSCT. [ 30 ] Unfortunately, a recent study reported by Rashidi et al [ 9 ] and How et al [ 32 ] was not included in this meta-analysis. Rashidi et al [ 9 ] showed that in AML patients undergoing allo-HSCT in MRD-negative CR1, a history of prior consolidation was associated with favorable outcomes.…”